Phase 1/2 Study Results of BCMA x CD3 Bispecific Monoclonal Antibody REGN5458 in Patients with RRMM

2021 Year in Review - Multiple Myeloma —February 23, 2022

Categories:

Multiple Myeloma

Updated analysis of the first-in-human phase 1/2 trial showed that BCMA x CD3 bispecific monoclonal antibody REGN5458 monotherapy resulted in early, deep, and durable responses with an acceptable safety and tolerability profile in heavily pretreated patients with RRMM.

The ongoing, first-in-human, phase 1/2 trial (NCT03761108) evaluated the safety and antitumor activity of the B-cell maturation antigen (BCMA) x CD3 bispecific monoclonal antibody REGN5458 in heavily pretreated patients with at least triple-refractory relapsed/refractory multiple myeloma (RRMM). Updated safety, overall response, and response durability of patients treated in the phase 1 portion of this study were reported at the 2021 ASH Annual Meeting and summarized here.

The study enrolled patients with progressive RRMM who were triple-refractory or intolerant to previous lines of systemic therapy, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 antibody. Eligible patients received REGN5458 monotherapy using a modified 3+3 dose-escalation design (4+3). Treatment consisted of 16 weekly infusions of REGN5458, followed by biweekly dosing until disease progression. The primary objectives of the phase 1 portion of the study were to assess the safety, tolerability, and occurrence of dose-limiting toxicities of REGN5458 and to determine a recommended phase 2 dose regimen. Key secondary end points were investigator-assessed objective response rate, duration of response (DOR), minimal residual disease status, pharmacokinetic analysis, and immunogenicity. The data cutoff date was September 30, 2021.

The dose-escalation cohort included 73 patients who received REGN5458 treatment across full doses ranging from 3 mg to 800 mg. The median age of the study cohort was 64 years; 21% of patients were aged ≥75 years, and 58% had Revised Multiple Myeloma International Staging System stage II and 23% had stage III. Patients had received a median of 5 previous lines of systemic therapy, and 38% were penta-refractory. The median duration of follow-up was 3 months.

Overall, the safety profile was consistent across all REGN5458 dose levels tested. Treatment-emergent adverse events (TEAEs) of any grade occurred in 100% of patients. The most common TEAEs included fatigue (45%), pyrexia (36%), and nausea (33%), which were mostly grade 1/2 severity. Treatment-related adverse events (TRAEs) occurred in 82.4% of patients; the most common hematologic TRAE was neutropenia (16.2%; grade ≥3, 13.2%) and the most common nonhematologic TRAEs were cytokine release syndrome (CRS; 38.2%) and fatigue (20.6%). Grade ≥3 TEAEs occurred in 42% of patients. CRS was reported in 28 (38%) patients, which were all grade 1/2; none discontinued treatment as a result of CRS. There were no grade ≥3 CRS or neurotoxicity events. There was no correlation between CRS and the full dose of REGN5458.

While responses were achieved across all dose levels, a response rate of 75% (18 of 24) was achieved among patients treated at the 200- to 800-mg dose levels. Across all dose levels, at least a very good partial response was achieved by 86% (N = 32) of all responders and complete response/stringent complete response was achieved by 43% (N = 16) of responders. The patient subgroup without extramedullary plasmacytomas achieved higher responses than those with extramedullary plasmacytomas. Median DOR was not reached; a high probability (90.2%) of DOR ≥8 months was estimated. Disease response did not correlate with BCMA expression levels.

Updated analysis of the phase 1/2 trial was promising, showing that REGN5458 monotherapy resulted in early, deep, and durable responses with an acceptable safety and tolerability profile in heavily pretreated patients with RRMM.

Source: Zonder JA, Richter J, Bumma N, et al. Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific monoclonal antibody, in a phase 1/2 first-in-human study in patients with relapsed/refractory multiple myeloma (RRMM). Blood. 2021;138(suppl 1):160.

Related Articles
Multiple Myeloma Year in Review Introduction
2022 Year in Review - Multiple Myeloma
This edition of Year in Review is focused on multiple myeloma (MM), a disease for which the treatment landscape has seen tremendous growth resulting in major favorable changes in patient outcomes. New treatments have been approved and novel classes of agents continue to be investigated, particularly in the relapsed/refractory multiple myeloma (RRMM) setting. We are providing this Year in Review series to disseminate the latest information on treatment advances in 2022 to clinicians in a timely and effective manner.
Addition of ASCT to Triplet Induction and Lenalidomide Maintenance to Progression: Results from the DETERMINATION Trial
2022 Year in Review - Multiple Myeloma
The addition of ASCT to triplet induction with lenalidomide, bortezomib, and dexamethasone (RVd) and lenalidomide maintenance resulted in significant PFS benefit versus RVd alone.
Daratumumab + Cyclophosphamide, Bortezomib, and Dexamethasone Induction Followed by Daratumumab Maintenance Achieved Durable Responses in Patients with RRMM and NDMM
2022 Year in Review - Multiple Myeloma
Final results from LYRA demonstrated robust responses with dara + CyBorD induction, which deepened with dara maintenance.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country